The effects of starting statin therapy prior to percutaneous coronary intervention with drug-eluting stent on postprocedural myonecrosis and clinical outcome

Acta Cardiologica Sinica

Volumn 23, Issue 2, 2007, Pages 71-78

  Jen, Hsu Lung ^a   Yin, Wei Hsian ^a   Chiang, Meng Cheng ^a   Wang, Jiann Jong ^a   Huang, Wen Pin ^a   Feng, An Ning ^a   Yang, Yung Nien ^a   Lin, Chang Chyi ^a   Tung, Tao Hsin ^a   Young, Mason Shing ^a  

^a CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

Author keywords

Clinical outcome; Drug eluting stent; Myonecrosis; Percutaneous coronary intervention; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; CREATINE KINASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; TICLOPIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 34547765297     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
3. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
4. Ruygrok PN, de Jaegere PT, van Domburg RT, et al. Clinical outcome 10 years after attempted percutaneous transluminal coronary angioplasty in 856 patients. J Am Coll Cardiol 1996;27:1669-77.
5. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-80.
6. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
7. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow-and moderate-release polymerbased paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-94.
8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
9. Pasceri V, Parti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: result from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8.
10. Chang SM, Yazbek N, Lakkis NM. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 2004;62:193-7.
11. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographie restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.
12. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
13. Chan AW, Bhatt DL, Chew DP, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002;105:691-6.
14. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6.
15. Walter DH, Fichtischerer S, Sellwig M, et al. Preprocedual C-reactive protein levles and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-46.
16. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
17. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
18. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8.
19. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome. Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation 2004;110:1061-8.
20. Bertrand ME, McFadden EP, Fruchart JC, et al. Effect of pravastatin on angiographic restenosis aftger coronary balloon angioplasty. J Am Coll Cardiol 1997;30:863-9.
21. Weintraub WS, Boccuzzi SJ, Klein JL, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-7.